Hallucinations in Psychotic Disorders
=====================================

Auditory hallucinations (AH) are a frequent symptom of schizophrenia which occurs in about 60--80% of patients ([@B2]). The content of these hallucinations is mostly negative, often conveying anger ([@B25]), or terms of abuse ([@B31]) and increasing the risk for suicidal behavior ([@B17]). Furthermore, AH also occur in other diagnostic groups such as borderline personality disorder, anxiety disorders, affective disorders, posttraumatic stress disorder, autism, and significant hearing loss ([@B48]).

In approximately 70--75% of these cases, antipsychotic medication and/or cognitive behavioral therapy sufficiently suppress AH. However, the remaining 25--30% continues to suffer from AH despite optimal therapy ([@B41]). Alternative treatment options are scarce for this group of patients, and often focus on coping with the hallucinations and accepting their presence instead of reducing them ([@B3]). Due to the distressing impact AH have on the patients' quality of life, their ability to concentrate and their social and professional functioning, finding an effective treatment option to reduce AH in this treatment-resistant group would be of great value.

Transcranial Direct Current Stimulation
=======================================

Transcranial direct current stimulation (tDCS) is a non-invasive focal neurostimulation technique that involves the application of a low intensity electric current between two surface electrodes, an anode and a cathode ([@B33]). A 1--2 mA direct current is applied between two electrodes, often with a size of 35 cm^2^ (5 cm × 7 cm), which are placed on the scalp. The current flows between the anode and the cathode, some of it being diverted through the scalp and another part moving through the brain where brain activity is modulated. Although the exact mechanisms of action of tDCS have yet to be completely elucidated, there are two mechanisms by which tDCS modulates brain activity that are currently widely accepted in the field ([@B7]). The first proposes that the current that passes through the brain modulates levels of cortical excitability in a polarity dependent manner ([@B27]). Cortical excitability is thought to be increased in the vicinity of the anode and reduced near the cathode. The anodal and cathodal effects of tDCS on cortical excitability are thought to be explained by shifts in the resting membrane potential (depolarization and hyperpolarization). The second proposes that prolonged effects of tDCS can be explained by modifications of *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor efficacy, changes in gamma-aminobutyric acid-ergic activity and modulation of interneurons, resulting in prolonged synaptic efficacy changes ([@B33]; [@B49]). However, most of what we know about the effects of tDCS on a neural level is derived from studies of the primary motor cortex ([@B33]). Questions can be raised concerning the generalizability of these underlying mechanisms to other cortical areas ([@B20]).

In the 1960s, tDCS was studied extensively, but never gained much popularity in clinical practice ([@B36]). Currently, this seems to be changing as tDCS is increasingly explored for the treatment of both neurologic and psychiatric symptoms ([@B4]). It has shown efficacy on the clinical symptoms of depression, on both depressive and manic symptoms of bipolar disorder, cognitive functioning in schizophrenia, episodic memory in Alzheimer's disease, motor symptoms and working memory in Parkinson's disease, on the amount of insults in epilepsy, on rehabilitation of motor function, and language disorder after stroke and on tinnitus ([@B14]; [@B24]). tDCS is a safe treatment with few, if any, side effects ([@B33]). Some mild side effects of a transient nature that have been mentioned in association with tDCS are a slight headache, an itching or tingling sensation at the location of the electrodes and redness of the skin at the location of the electrodes. However, such side effects are also reported after placebo (sham) treatment ([@B8]). Other advantages of this technique are that tDCS equipment is relatively cheap, the treatment can be given after a short training course, and it is easily portable.

Compared to transcranial magnetic stimulation (TMS), another form of focal stimulation that has often been used as an alternative treatment option for AH ([@B46]), tDCS has some explicit benefits when using it for research. It is easier to apply an identical placebo treatment, as less physical sensations occur compared to TMS. The itching or tingling sensation that is sometimes mentioned by participants is often only present at the start of treatment and disappears quickly. To mimic this in a placebo treatment, it helps to start with a short period of active stimulation (30--40 s) after which stimulation slowly regresses. During the rest of the treatment period, no active stimulation takes place. This short active stimulation period does not have modulating effects on the brain, but it properly mimics the physical sensations of active treatment. Furthermore, it is possible to preprogram tDCS equipment to apply placebo treatment, which makes it easier to perform double blind sham-controlled trials ([@B33]).

Transcranial Direct Current Stimulation in AH
=============================================

The use of tDCS as a treatment option for medication resistant AH is relatively new and has till now only been tested in patients with AH in the context of psychotic disorders. [@B19] were the first to explore this in a case study. For 10 consecutive days, the patient received daily treatment of 15 min tDCS at an intensity of 1 mA. The cathode was placed on the left temporoparietal cortex (TPC), a location that has been linked to the experience of AH ([@B44]; [@B40]). The anode was placed on the right supraorbital area. Using this method, they were able to ameliorate medication resistant AH. Moreover, this effect was still present 6 weeks after treatment. A more recent case study reported a reduction of 90% in AH severity after 2 months of daily 20 min tDCS at an intensity of 1 mA ([@B1]). After this, treatment was increased to twice daily and an intensity of 3 mA, which led to increased improvement in AH severity. This improvement was still present after 3 years of daily maintenance treatment, but when treatment frequency was reduced to once per 2 days the ameliorating effects disappeared. In this study, the cathode was also placed on the left TPC, but the anode was placed on the left dorsolateral prefrontal cortex (DLPFC). This is an area that is often used in studies investigating the effects of tDCS on cognitive functioning ([@B21]). These two tDCS locations have been used in several other case studies reporting positive effects of tDCS on AH severity after multiple sessions of 20 min tDCS at an intensity of 2 mA ([@B37]; [@B42]; [@B43]; [@B30]). However, all these studies were open-label without a control condition, meaning that non-specific effects (i.e., placebo-effects) may have been of large influence. [@B6] were the first to publish a tDCS study in AH in which a control group was included. In this study, 15 patients received a 20 min tDCS treatment twice daily at an intensity of 2 mA, for 5 consecutive days and an equal number of patients received sham. In this study, the cathode was also placed on the left TPC and the anode on the left DLPFC. They found a robust decrease in AH severity of 30% compared to a placebo group of equal size. Furthermore, a significant decrease was found in other symptoms as measured by the Positive and Negative Syndrome Scale (PANSS), such as negative symptoms. These positive effects were still present after 3 months. A more recent study by the same group, using a partially overlapping sample of 28 patients and identical methods, reported a decrease of 46% in AH frequency in medication resistant patients after active treatment, whereas no such effect occurred in the placebo group ([@B28]). A recent open label study including 21 patients with schizophrenia and the same stimulation parameters and locations as [@B6] found a similar improvement of 32% in AH severity. However, this study did not include a placebo condition ([@B5]). Up till now, one pilot study has been published that reports no beneficial effect of tDCS treatment on AH ([@B13]). This study tested the effects of both unilateral (*N* = 13) and bilateral (*N* = 11) tDCS on AH compared to placebo. In total, patients underwent 15 treatments in 3 weeks time. The AH did not respond to either treatment method. However, it is important to note that this study had a very small sample size and rated AH severity based on the PANSS only. This scale does not measure AH in much detail and the different severity scores of the hallucination item are found to be hard to differentiate ([@B39]). Other studies mostly use the Auditory Hallucination Rating Scale (AHRS) to measure AH severity. See **Table [1](#T1){ref-type="table"}** for a summary of all includedstudies.

###### 

Studies using tDCS for the treatment of auditory hallucinations (AH).

  Reference   Design                                               Patients                                                                                  Position of electrodes                                                                                                       Current strength         Duration                                                                                                               Effects
  ----------- ---------------------------------------------------- ----------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------ ---------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B1]       Case study                                           One subject with schizophrenia and clozapine resistant AH.                                The cathode over the left temporoparietal cortex (TPC) and the anode over the left dorsolateral prefrontal cortex (DLPFC).   First 1 mA, later 3 mA   First 20 min (daily sessions for 2 consecutive months), later 30 min (twice daily sessions for 3 consecutive years).   A reduction of 90% in AH severity was reported after the first 2 months. After increasing treatment to twice daily and a current intensity of 3 mA, AH severity further improved. When electrode positioning was changed or treatment frequency was reduced to once per 2 days, the ameliorating effects disappeared.
  [@B5]       Open label study, without a placebo condition        21 subjects with schizophrenia and medication resistant AH.                               The cathode over the left TPC and the anode over the left DLPFC.                                                             2 mA                     20 min (twice daily sessions on 5 consecutive days).                                                                   Improvement of 32% in AH severity.
  [@B6]       Randomized, placebo controlled, double-blind trial   30 subjects with schizophrenia and medication resistant AH.                               The cathode over the left TPC and the anode over the left DLPFC.                                                             2 mA                     20 min (twice daily sessions on 5 consecutive days).                                                                   Improvement of 31% in AH severity which lasted for 3 months.
  [@B13]      Randomized, placebo controlled, double-blind trial   24 subjects with schizophrenia or schizoaffective disorder and medication resistant AH.   Unilateral and bilateral tDCS with the cathode over the (left) TPC and the anode over the (left) DLPFC.                      2 mA                     20 min (daily sessions on 15 days in 3 consecutive weeks)                                                              AH did not respond to either treatment method, and no difference was found between the active and placebo treatment group.
  [@B19]      Case study                                           One subject with schizophrenia and medication resistant AH.                               The cathode over the left TPC and the anode over the right supraorbital area.                                                1 mA                     15 min (daily sessions on 10 consecutive days)                                                                         Amelioration of AH was reported, which was still present 6 weeks after treatment.
  [@B28]      Randomized, placebo controlled, double-blind trial   28 subjects with schizophrenia and medication resistant AH.                               The cathode over the left TPC and the anode over the left DLPFC.                                                             2 mA                     20 min (twice daily sessions on 5 consecutive days).                                                                   Improvement of 46% in AH severity in the active treatment group, with no such effect in the placebo group.
  [@B30]      Case study                                           One subject with schizophrenia and medication resistant AH.                               The cathode over the left TPC and the anode over the left DLPFC.                                                             2 mA                     20 min (twice daily sessions on 5 consecutive days).                                                                   Improvement of AH.
  [@B37]      Case study                                           One subject with schizophrenia and medication resistant AH.                               The cathode over the left TPC and the anode over the left DLPFC.                                                             2 mA                     20 min (twice daily sessions on 5 consecutive days).                                                                   Complete cessation of AH.
  [@B42]      Case study                                           One subject with schizophrenia and medication resistant AH.                               The cathode over the left TPC and the anode over the left DLPFC.                                                             2 mA                     20 min (twice daily sessions on 5 consecutive days).                                                                   Improvement of AH, which was sustained after a 2-month follow-up.
  [@B43]      Case study                                           One subject with schizophrenia and medication resistant AH.                               The cathode over the left TPC and the anode over the left DLPFC.                                                             2 mA                     20 min (twice daily sessions on 5 consecutive days).                                                                   Complete cessation of AH, which was sustained after a 4-week follow-up.

It is still unclear in what way tDCS might influence AH. As all studies that report positive results up till now have used the left TPC as the location for the cathode, it appears that the inhibiting action of tDCS on that specific location is important for the beneficial effects. It is unclear if excitation on the left DLPFC also influences AH severity. [@B6] associated excitation on this location with a decrease of negative symptoms. However, [@B1] found that using a more neutral position for the anode, namely the left mastoid, caused the beneficial effects on AH to vanish. This implicates that the excitatory effect of the anode on the DLPFC is important to induce a beneficial effect on AH. Possibly this can be explained by a positive effect from anodal stimulation of the left DLPFC on working memory. This hypotheses is mainly derived from literature on tinnitus, for which tDCS has also been reported to be effective. Like schizophrenia, tinnitus has been associated with reduced executive control ([@B18]). Besides, tinnitus has been found to be alleviated by tDCS over the DLPFC ([@B15]). These authors hypothesized that improved executive control, as induced by tDCS over the DLPFC, acts as a mediator for the impact from tDCS on tinnitus ([@B18]). It may be that a similar therapeutic mechanism is involved in the therapeutic effect of tDCS for AH. Reduced inhibition of irrelevant verbal information may be an important underlying mechanism of AH, speculatively AH could result from misattribution of self-generated information to an external source ([@B10]). Application of anodal tDCS over de left DLPFC has been found to enhance working memory, which plays an important role in the executive control of information ([@B9]). It could therefore be speculated that anodal tDCS over the left DLPFC induces the ameliorating effects on AH by improving the inhibition of irrelevant verbal information. Whether this excitation must take place at the left DLPFC is, however, yet unclear, as the first case study in this field used the right supraorbital area for the anode and still showed a positive result ([@B19]). Moreover, tDCS does not only produce focal effects but also indirect effects on surrounding brain areas and their connections ([@B23]). The more distal effects of tDCS could also be of influence on the ameliorating effects on AH. Imaging studies combined with tDCS in AH could provide more insight in the exact neurological underpinnings of the effects of this treatment.

Taken together, the results of tDCS as an alternative treatment option for AH are preliminary and so far mostly positive. However, a note of caution may be in place here. When new treatment strategies are introduced, the initial reports tend to feature relatively small sample sizes and favorable results, whereas small studies with negative findings do not tend to be published ([@B11]; [@B47]). With an increase of studies with larger sample sizes over time, negative findings tend to become published as well. Such trends have led effect sizes to decrease per year of publication ([@B29]). This effect has also been visible in the application of TMS for AH ([@B45]). As tDCS in the treatment of AH is a young treatment method, future studies may well show less favorable results. In the University Medical Center Utrecht, we have started a large randomized double blind trial to investigate the effects of tDCS on AH. We plan to include 62 patients and expect to be able to report results in autumn 2015. It is important to await such studies with large sample sizes before conclusions are drawn about the efficacy of tDCS. This also means that there is a large responsibility for scientific periodic journals to also publish negative findings of such treatments, to help reduce publication bias for positive results.

Moreover, it is of importance that placebo treatments in double blind trials are hard to distinguish from active tDCS treatment. At this point, all placebo-controlled trials in this field have used tDCS at an intensity of 2 mA ([@B6]; [@B13]; [@B28]). For 1 mA tDCS, it has been reported that placebo treatment is highly identical to active treatment. Both participants and investigators were not able to distinguish between the two ([@B16]). This provides confidence that both participants and investigators will remain well blinded throughout the duration of a double blind trial. However, it is yet unsure if the same applies for tDCS stimulation at 2 mA, as the physical sensations at this intensity are more pronounced and redness of the skin may occur. Although the literature is still unclear if participants themselves are able to differentiate between 2 mA active stimulation and placebo treatment, it has been found that redness of the skin is a possible clue for researchers to differentiate between the two ([@B34]; [@B35]). However, it is important that these results stem from crossover studies, in which subtle differences between treatments and the effects on each individual participant attract more attention. [@B8] investigated tDCS blinding of 2 mA stimulation in a large sample of patients with a depression disorder, using a parallel design. Each patient received either active or placebo treatment. They found that patients were able to identify 2 mA active treatment above chance level, but this appeared to be related to the occurrence of clinical response. Patients who did not show clinical response to treatment were not able to identify active treatment. However, this study did not mention results about the accuracy of blinding in tDCS operators, which were different investigators than the assessors of the clinical effect of the treatment. Knowing if a parallel design has advantages for the accuracy of blinding in tDCS operators is important to assess the reliability of results from double blind studies using placebo-controlled tDCS in parallel designs.

At this time, studies using tDCS in AH have highly similar methods, using 15--20 min of treatment at 1--2 mA and mostly placing the electrodes over the left TPC and left DLPFC. Future research could further investigate if these are indeed the most optimal parameters and locations for tDCS in AH. In TMS, the left TPC is also the most used brain area for inhibitory stimulation as a treatment for AH. Multiple attempts at other locations for TMS did not lead to positive results compared to placebo ([@B46]). Considering that, the choice for the left TPC as a location for the cathode in tDCS seems logical. However, it may be worth the effort to test the efficacy of both cathodal and anodal tDCS on other brain areas that have been associated with AH.

Furthermore, the precision of the treatment in influencing the targeted brain areas could possibly be optimized. In most studies, relatively large electrodes are used with a surface size of 35 cm^2^. However, it is also possible to use smaller electrodes with a surface size of 25 cm^2^ or even so called 'high definition' tDCS in which electrodes are used with a diameter of 12 mm or less ([@B26]). Such a method may increase the precision of treatment by decreasing the amount of electricity that is lost due to distribution over the scalp. But using smaller electrodes should be investigated thoroughly, as the neuromodulating effects of small electrodes can strongly differ from those of big electrodes ([@B33]). It is possible that the desired effects are eliminated instead of increased using small electrodes, as they are designed for more focal effects and will have less effect on surrounding brain areas and their connections. The use of small electrodes also increases the need for more precision in placing the electrodes on the scalp. Currently, electrode placement is mostly done using the international 10--20 system for EEG electrode placement ([@B22]), but it is unclear whether this offers enough precision when using smaller electrodes. A stereotactic neuronavigation technique based on an individual's structural MRI image may be a suitable option to offer more reliability that the focus of tDCS treatment is targeted at the right brain area ([@B32]; [@B12]; [@B38]).

Conclusion
==========

At this moment, tDCS appears to be a possible new treatment option to help reduce treatment-resistant AH. However, as currently only three randomized controlled trials have been published with relatively small sample sizes, two of which reporting positive results and one with non-significant results, insufficient data is available to determine if tDCS treatment is indeed effective in AH. Future placebo-controlled trials in large samples will have to assess if the mainly positive results up till now can be replicated. Furthermore, different methods and parameters for stimulation, localization, and precision of tDCS should be investigated in more detail to further optimize this treatment.
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